
Sign up to save your podcasts
Or
Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
3.8
4747 ratings
Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
130 Listeners
319 Listeners
160 Listeners
862 Listeners
494 Listeners
21 Listeners
32 Listeners
87 Listeners
135 Listeners
1,081 Listeners
39 Listeners
186 Listeners
414 Listeners
35 Listeners
136 Listeners